CJC1295 5mg (w/o Dac) Ipa 5mg

Synergistic Growth Hormone Secretagogue Combination for Pulsatility Research

This research product combines two well-characterized peptides—CJC-1295 (without the Drug Affinity Complex) and Ipamorelin—into a standardized blend for laboratory investigation. This combination allows researchers to study potential synergistic effects on growth hormone secretion by simultaneously activating both the Growth Hormone-Releasing Hormone (GHRH) receptor (via CJC-1295) and the ghrelin/Growth Hormone Secretagogue Receptor (GHSR-1a) (via Ipamorelin). CJC-1295 (no DAC) acts as a potent, short-acting GHRH analog, while Ipamorelin is a selective GHSR-1a agonist known for its clean profile. Together, they provide a research tool to investigate the hypothesis that co-activation of both primary pathways controlling GH secretion may produce a more robust and physiological pulsatile release profile in experimental models than either compound alone. Supplied as a pre-mixed lyophilized powder, this combined formulation is intended strictly for controlled, non-human laboratory research exploring advanced endocrinology and pulsatile hormone dynamics.

Complete Research Kit Contents & Verification

Each research order provides a complete experimental package designed for sophisticated endocrine research:

• Primary Research Compound: 10 sterile glass vials containing 5mg of lyophilized peptide blend per vial (2.5mg CJC-1295 (no DAC) + 2.5mg Ipamorelin Acetate).

• Reconstitution Solution: 30ml vial of sterile Bacteriostatic Water (0.9% Benzyl Alcohol), essential for creating stable peptide solutions for experimental use.

• Laboratory Administration Tools: Pack of sterile 1ml insulin syringes (29G x 1/2″) for precise measurement and transfer in accordance with research protocols.

• Sterilization Supplies: Individually wrapped alcohol prep swabs to maintain aseptic technique.

• Research Protocol Documentation:

  • Dosing Schedule: Standardized administration protocol for research models focusing on combined secretagogue studies, pulsatility timing experiments, and aging/endocrine axis research.

  • Usage Instructions: Comprehensive guide covering reconstitution math, storage conditions (-20°C recommended for both peptides), handling safety, and experimental design considerations for timing-dependent combination studies.

• Quality Verification: Dual Certificate of Analysis (CoA) provided with each batch, detailing for EACH peptide component:

  • CJC-1295 (no DAC) Component (sequence: H-Y-D-A-I-F-T-N-S-Y-R-K-V-L-G-Q-L-S-A-R-K-L-L-L-D-I-M-S-R-Q-Q-G-E-S-N-Q-E-G-R-K-R-Y-NH₂):

    • Purity Analysis (>98% by HPLC)

    • Sequence Verification (Mass Spectrometry)

    • Molecular Weight: 3637.2 Da Confirmed

    • Confirmation of NO Drug Affinity Complex (DAC) – Critical Specification

  • Ipamorelin Acetate Component (Aib-His-D-2-Nal-D-Phe-Lys-NH₂):

    • Purity Analysis (>98% by HPLC)

    • Sequence & Modification Verification (Aib, D-2-Nal)

    • Molecular Weight: ~771.9 Da (Acetate Salt) Confirmed

  • Blend Verification:

    • Precise 1:1 Ratio Confirmation (2.5mg ±0.1mg each)

    • Sterility Testing Results (Combined)

    • Endotoxin Levels (<10 EU/mg total)

    • Homogeneity Testing

Research Applications & Scientific Utility

In a laboratory setting, this combined peptide blend enables investigation into synergistic GH secretagogue mechanisms. Primary research applications include studying the amplification of pulsatile GH release through complementary receptor activation (GHRH-R + GHSR-1a), researching potential mitigation of receptor desensitization by using two distinct pathways, investigating age-related decline in GH secretion using a multi-target approach, exploring the metabolic and tissue-specific effects of enhanced pulsatile GH profiles, and serving as a comparator to single-mechanism secretagogues or to the long-acting CJC-1295 with DAC. This combination allows researchers to test sophisticated hypotheses about hypothalamic-pituitary feedback and the integration of different secretagogue signals.

Laboratory Handling & Safety Protocol

• Storage: Store unopened lyophilized peptide blend vials at -20°C or below. Both peptides are stable under these conditions. Reconstituted solutions should be aliquoted and stored at -20°C.

• Reconstitution: Must be performed under sterile laboratory conditions. The blend is designed for complete solubility. Swirl gently to dissolve.

• Laboratory Safety: Standard personal protective equipment (PPE) is required. Follow institutional biosafety guidelines.

• Timing Considerations: For pulsatility research, precise timing of administration and blood sampling is critical. The complementary mechanisms may have different onset kinetics.

⚠️ Critical Compliance & Intended Use Disclaimer:

THIS PRODUCT IS SOLD FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

1. Intended Use: This CJC-1295 & Ipamorelin blend is supplied as a combined biochemical reagent for laboratory research purposes only. It is intended for use by qualified researchers in controlled settings studying advanced endocrinology. The “dosing schedule” refers to research model protocols only.

2. Not for Human Consumption: Under no circumstances is this product intended for administration to humans or animals. It is not an anti-aging, performance enhancement, or bodybuilding supplement. The provided supplies are for laboratory use only.

3. Regulatory Status: This product and its components have not been evaluated or approved by the FDA or any global health authority for any therapeutic use.

4. Specificity Notice: CRITICAL – This product contains CJC-1295 WITHOUT DAC, which has a short half-life, unlike the long-acting CJC-1295 with DAC. This distinction is crucial for research design and must be clearly understood by the researcher.

5. Researcher Responsibility: It is the sole responsibility of the purchasing institution to ensure compliance with all regulations and to use this combination product only for legitimate, non-human research.